Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 1;17(4):261-270.
doi: 10.2217/pme-2019-0135. Epub 2020 Jun 26.

CYP2D6 does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment

Rangel-Méndez Jorge-Aarón  1 , Rubi-Castellanos Rodrigo  2 , Ascencio-Montiel Iván de Jesús  3 , Moo-Puc Rosa Esther  1
Affiliations

CYP2D6 does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment

Rangel-Méndez Jorge-Aarón et al. Per Med. .

Abstract

Aim: We conducted a retrospective analysis in 71 Mexican Mestizo patients to evaluate the breast cancer-free survival (BCFS) among the inferred genetic phenotypes (GP) of CYP2D6. Patients & methods:CYP2D6 was genotyped through Taqman-probe analysis; GP were inferred according to international guidelines. The BCFS was estimated through Kaplan-Meier method and analyzed with a log-rank test; hazard ratios were calculated with 95% CI and p < 0.05. Results: The BCFS did not differ among CYP2D6 GP (p = 0.45) and recurrence risk was similar between gNM + gUM and gPM + gIM groups (hazard ratio: 1.54, 95% CI: 0.37-6.38; p = 0.55). Conclusion: The findings do not support any impact of CYP2D6 on BCFS. Evaluation of other genetic/nongenetic biomarkers is needed in Mexican Mestizo patients under tamoxifen treatment.

Keywords: CYP2D6; breast cancer-free survival; genetic phenotype; mexican mestizos; recurrence; tamoxifen.

PubMed Disclaimer

Publication types